Delirium, Intraoperative Cerebral Perfusion and EEG Abnormalities After Total Hip Arthroplasty

December 21, 2020 updated by: University of Pennsylvania

Pathophysiology of Delirium in Patients Undergoing Total Hip Arthroplasty: Role of Intraoperative Cerebral Perfusion and EEG Abnormalities

The overall objective of this study is to test for perturbations in intraoperative electroencephalogram (EEG) , cerebral blood flow (CBF), cerebral metabolic rate of oxygen consumption (CMRO2), oxygen extraction fraction (OEF), and serum and cerebral spinal fluid biomarkers associated with delirium in high risk population having elective hip arthroplasty at Penn Presbyterian Medical Center (PPMC).

Study Overview

Detailed Description

All prospective patients will be given a copy of the informed consent which explains the details and responsibilities of the study.

Each patient will have a preoperative baseline 3D-CAM and MOCA to document preoperative cognitive function and possible criteria for exclusion.

  1. The 3D -Confusion Assessment Method (CAM) test is a clinician evaluation and algorithm for the binary determination of presence or absence of delirium.
  2. Montreal Confusion Assessment (MOCA) - to be given preoperatively to determine if element of pre-existing cognitive impairment

Intraoperatively each patient will have a NIR Optode patch placed to measure intraoperative cerebral blood flow and oxygen extraction fraction and cerebral metabolic rate of oxygen consumption.

A non-invasive frontal EEG patch will be placed prior to or at the start of anesthesia. Anesthetic depth will be measured using the SEDline® by Masimo. Continuous raw EEG, spectral edge, compressed spectral analysis and percentage suppressed will be recorded from the SEDline® monitor.

The investigators will be drawing blood from patients who agree to participate in the study. Preoperative blood sampling will be done while the investigators place the intravenous line, or if present, from an arterial line.

If a spinal anesthetic is being used, 5 mL of cerebral spinal fluid (CSF) will be collected at the time of dural puncture prior to the administration of the neuraxial blockade.

Members of the research team will administer 3D-CAM testing on post-operative days 1 and 2.

Study Type

Observational

Enrollment (Actual)

3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients undergoing total joint arthroplasty who are 65 years of age and older.

Description

Inclusion Criteria:

  1. Patients 65 years of age and over scheduled for elective total joint arthroplasty
  2. Mentally competent and able to give consent for enrollment in the study
  3. Patients at any age with a pre-existing diagnosis of dementia or acquired cognitive deficit. Consented by legally authorized representative (LAR).

Exclusion Criteria:

  1. Patients currently delirious
  2. Acute neurological disease like stroke or brain tumor
  3. Current alcohol or substance abuse at risk of postoperative withdrawal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Delirium

Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.

Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.

CSF collected for biomarkers. Blood colelcted for biomarkers.

5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
Other Names:
  • CSF
Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
Other Names:
  • EEG
NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
Non-delirium

Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.

Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.

CSF collected for biomarkers. Blood colelcted for biomarkers.

5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
Other Names:
  • CSF
Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
Other Names:
  • EEG
NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delirium Rating Scale
Time Frame: change from Baseline through day 2 post op
The severity of delirium in this patient population as quantified by the DRS
change from Baseline through day 2 post op
Serum biomarkers
Time Frame: change from Baseline through day 2 post op
The change in serum biomarkers S100β in patients who are diagnosed with delirium by DRS.
change from Baseline through day 2 post op

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cerebral blood flow
Time Frame: change from Baseline through 3 hours
Changes in CBF from the norm in the patients who develop delirium
change from Baseline through 3 hours
Confusion Assessment Method
Time Frame: change from Baseline through day 2 post op
Changes in patient performance to determine the presence or absence of delirium as measured by the CAM test
change from Baseline through day 2 post op

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrew W Kofke, MD MBA FCCM, University of Pennsylvania

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2016

Primary Completion (Actual)

December 1, 2020

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

June 2, 2016

First Submitted That Met QC Criteria

June 27, 2016

First Posted (Estimate)

June 30, 2016

Study Record Updates

Last Update Posted (Actual)

December 23, 2020

Last Update Submitted That Met QC Criteria

December 21, 2020

Last Verified

December 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on Blood Draw

3
Subscribe